← Back to patent-cliff list
CAS 87128-98-1
2,2,4-Trimethylcyclohex-3-en-1-one
Codes: (XLIII)101438-55-d
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1,3-Dihydroxy-2,2-dimethylpropane→2,2-Dimethylcyclohexane-1,3-dione→2,2,4-Trimethylcyclohex-3-en-1-one→2,4,6-Triisopropyl-N'-[(1Z)-2,2,4-trimethylcyclohex-3-en-1-ylidene]benzenesulfonohydrazide→2,4,6-Triisopropylbenzenesulfonohydrazide→3,3,7,7-Tetramethyl-1,5-dioxaspiro[5.5]undecan-8-one→3,3,7,7,9-Pentamethyl-1,5-dioxaspiro[5.5]undec-8-ene→3,5-Cyclohexanedione→4-Methyl-N'-[(8E)-3,3,7,7-tetramethyl-1,5-dioxaspiro[5.5]undec-8-ylidene]benzenesulfonohydrazide→4-Methylbenzenesulfonhydrazide→Iodomethane
1,3-Dihydroxy-2,2-dimethylpropane→2,2-Dimethylcyclohexane-1,3-dione→2,2,4-Trimethylcyclohex-3-en-1-one→2,4,6-Triisopropyl-N'-[(1Z)-2,2,4-trimethylcyclohex-3-en-1-ylidene]benzenesulfonohydrazide→2,4,6-Triisopropylbenzenesulfonohydrazide→3,3,7,7-Tetramethyl-1,5-dioxaspiro[5.5]undecan-8-one→3,3,7,7,9-Pentamethyl-1,5-dioxaspiro[5.5]undec-8-ene→3,5-Cyclohexanedione→4-Methyl-N'-[(8E)-3,3,7,7-tetramethyl-1,5-dioxaspiro[5.5]undec-8-ylidene]benzenesulfonohydrazide→4-Methylbenzenesulfonhydrazide→Iodomethane
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.